Market Research Logo

Global Cystic Fibrosis Therapeutics Market 2016-2026

Global Cystic Fibrosis Therapeutics Market 2016-2026

The latest report from business intelligence provider visiongain offers comprehensive analysis of the global cystic fibrosis market. Visiongain expects the global cystic fibrosis market to grow at a CAGR of 16.7% from 2016 to 2021. The global cystic fibrosis market is estimated to reach $7.7bn by 2021.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this 191-page report you will receive 113 tables, charts and graphs – all unavailable elsewhere.

The 191 page report provides clear detailed insight into the global cystic fibrosis market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope

Global Cystic Fibrosis market forecasts from 2016-2026

Cystic Fibrosis submarket forecasts from 2016-2026 covering:

  • Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators
  • Protein Transcription Modulators
  • Pancreatic Enzyme Products (PEP)
  • Other therapies
Individual drug revenue forecasts from 2016-2026 by pharmacological classes:
  • Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators:
Orkambi

Kalydeco

VX-661 + ivacaftor

Second corrector/VX-661/ivacaftor
  • Protein Transcription Modulators
Pulmozyme

QR-010

Translarna
  • Pancreatic Enzyme Products (PEP)
Ceron
  • Other therapies
Cayston

TOBI

Revenue forecasts from 2016-2026 and discussion of relevant trends and developments in the leading national cystic fibrosis market

Analysis of the key factors driving growth in the global, regional and country level of the Cystic Fibrosis Market from 2016-2026

Patent and clinical trials information of the marketed and pipeline products for cystic fibrosis

The dynamic of pricing, patient share and market share of the leading cystic fibrosis drugs in the US and Europe

Discussion on selected leading companies marketing and developing cystic fibrosis drugs:
  • Vertex Pharmaceuticals
  • Roche
  • AbbVie
  • Gilead Sciences
  • Novartis
Visiongain’s study is intended for anyone requiring commercial analyses for the Cystic Fibrosis Market and leading companies. You find data, trends and predictions.

Please Note: Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.

The publisher is using a password system to access all reports. Single user (non-printable) and departmental licenses expires after 12 month period. In the case of departmental site license purchases, the publisher requires all email addresses for the licensed users prior to fulfillment.


1. Report Overview
1.1 Global Cystic Fibrosis Market Overview
1.2 Why You Should Read This Report
1.3 Structure of the Report
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report Include:
1.6 Who is This Report For?
1.7 Methodology
1.7.1 Primary Research
1.7.2 Secondary Research
1.7.3 Market Evaluation & Forecasting Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated visiongain Reports
1.10 About visiongain
2. Introduction to the Cystic Fibrosis Market
2.1 An Overview of Cystic Fibrosis
2.2 Genetics Associated With Cystic Fibrosis
2.2.1 CFTR Chromosome Location
2.2.2 CFTR Mutations
2.2.3 Inheritance Pattern
2.3 New-born Screening for Cystic Fibrosis
2.4 Signs and Symptoms
2.4.1 Respiratory Inflammation and Infections
2.4.2 Gastrointestinal Tract Symptoms
2.4.3 Fertility and Reproduction Related Issues
2.5 Diagnosis
2.5.1 Sweat Testing
2.5.2 Nasal Potential Measurements Voltage
2.5.3 Genotyping
2.5.4 Ancillary Testing
2.6 Treatment
2.6.1 Gene Therapy
2.6.2 Symptomatic Treatment
2.6.2.1 Respiratory Care
2.6.2.2 Inhaled Bronchodilators
2.6.2.3 Airway Clearance
2.6.2.4 Antibiotics
2.6.2.5 Lung Transplant
2.6.2.6 Other Treatments
2.7 Prognosis
2.8 Quality of Life
2.9 Epidemiology
2.9.1 Epidemiology Trends in the US
2.9.1.1 Age Distribution of Cystic Fibrosis Patients in the US
2.10 Epidemiology Trends in Europe
2.10.1 Age Distribution of Cystic Fibrosis Patients in Europe
2.11 Epidemiology Trends in Canada
2.12 Epidemiology Trends in RoW
2.13 Epidemiology Trends of F 508 Del Mutations
3. Global Cystic Fibrosis Market 2016-2026
3.1 Cystic Fibrosis Regional Markets 2016-2026
3.1.1 US Cystic Fibrosis Market Forecast 2016-2026
3.1.1 Cost per Patient per Year (US)
3.1.2 Price Increase of Cystic Fibrosis Drugs YoY (US)
3.1.3 Patients Treated by Various Drugs (US)
3.1.4 Patient Share vs Market Share of Top Products (US)
3.2 Europe Cystic Fibrosis Market Forecast 2016-2026
3.3 RoW Cystic Fibrosis Market Forecast 2016-2026
3.3.1 Cystic Fibrosis Japan Market
3.4 Cystic Fibrosis Regional Market Forecast 2016-2026
4. Cystic Fibrosis market – By Pharmaceutical class 2016-2026
4.1 Cystic Fibrosis market – CFTR Modulators 2016-2026
4.1.1 Orkambi (Vertex Pharmaceuticals) market – CFTR Modulators 2016-2026
4.1.2 Kalydeco (Vertex Pharmaceuticals) market – CFTR Modulators 2016-2026
4.1.3 VX-661 + ivacaftor (Royalty Pharma) market – CFTR Modulators 2016-2026
4.1.4 Second corrector/VX-661/ivacaftor (Vertex Pharmaceuticals) market – CFTR Modulators 2016-2026
4.1.5 Cross Comparison of CFTR Modulators Forecast 2016-2026
4.2 Cystic Fibrosis market – Protein Transcription Modulators 2016-2026
4.2.1 Pulmozyme (Roche) market – Protein Transcription Modulators 2016-2026
4.2.2 QR-010 (ProQR Therapeutics) – Protein transcription Modulators 2016-2026
4.2.3 Translarna (PTC Therapeutics) market – CFTR Modulators 2016-2026
4.2.4 Cross Comparison of Protein Transcription Modulators Forecast 2016-2026
4.3 Cystic Fibrosis market – Ceron (AbbVie), Pancreatic enzyme product (PEP) 2016-2026
4.4 Cystic Fibrosis market – Other Therapies 2016-2026
4.4.1 Cayston (Gilead Science) Market Forecast 2016-2026
4.4.2 TOBI (Novartis) Market Forecast 2016-2026
4.5 Cross Comparison of Pharmacological Class Forecast in CF 2016-2026
5. Timeline of Product Launches, Patent analysis and Deal analysis for Key Therapies
5.1 Timeline of US Product Launches – Key Therapies
5.2 Timeline of Europe Product Launches – Key Therapies
5.3 Timeline of Japan Product Launches – Key Therapies
5.4 Patent analysis in Cystic Fibrosis – Key Therapies
5.4.1 Patent analysis of Launched Products – Key Therapies
5.4.2 Patent analysis of Phase 3 Products – Key Therapies
5.4.3 Patent analysis of Phase 2 Products – Key Therapies
5.4.4 Patent analysis of Phase 1 Products – Key Therapies
5.4.5 Patent analysis of pre-clinical and research stage products – Key Therapies
5.5 Deal analysis in Cystic Fibrosis – Key Therapies
6. Product Profiles in Cystic Fibrosis – Key Therapies
6.1 Orkambi (Vertex Pharmaceuticals) Product Profile
6.2 Kalydeco (Vertex Pharmaceuticals) Product Profile
6.3 Pulmozyme (Roche) Product Profile
6.4 Translarna (PTC Therapeutics) Product Profile
6.5 Tezacaftor (Vertex Pharmaceuticals) Product Profile
6.6 Ivacaftor and tezacaftor (Vertex Pharmaceuticals) Combination Product Profile
7. Company Profiles
7.1 Vertex Company Profile
7.1.1 Vertex Company Overview
7.1.2 Vertex Projects Overview
7.1.3 Vertex Recent Deals
7.1.4 Key Product sales (2010-2020)
7.2 Roche Company Profile
7.2.1 Roche Company Overview
7.2.2 Roche Projects Overview
7.2.3 Roche Recent Deals
7.2.4 Roche Key Product sales
7.3 AbbVie Company Profile
7.3.1 AbbVie Company Overview
7.3.2 AbbVie Projects Overview
7.3.3 AbbVie Recent Deals
7.3.4 AbbVie Key Product Sales
7.4 Gilead Sciences Company Profile
7.4.1 Gilead Company Overview
7.4.2 Gilead Projects Overview
7.4.3 Gilead Recent Deals
7.4.3 Gilead Key Product Sales
7.5 Novartis Company Profile
7.5.1 Novartis Company Overview
7.5.2 Novartis Projects Overview
7.5.3 Novartis Recent Deals
7.5.3 Novartis Key Product Sales
8. Qualitative Analysis of the Cystic Fibrosis Market
8.1 Strengths of the Cystic Fibrosis Market
8.2 Weaknesses of the Cystic Fibrosis Market
8.3 Opportunities for the Cystic Fibrosis Market
8.4 Threats for the Cystic Fibrosis Market
8.5 Political Factors Influencing the Cystic Fibrosis Market
8.6 Economical Factors Influencing the Cystic Fibrosis Market
8.7 Social Factors Influencing the Cystic Fibrosis Market
8.8 Technological Factors Influencing the Cystic Fibrosis Market
9. Conclusions
9.1 Cost of Therapies in Cystic Fibrosis
9.2 Patient vs Market Share Trends in Cystic Fibrosis
9.3 Global Cystic Fibrosis Market Trends from 2016 to 2026
9.4 Geographical trends of Cystic Fibrosis Market
9.5 Cystic Fibrosis Market as per Pharmacological Class
10. Glossary
Associated Visiongain Reports
Visiongain Report Sales Order Form
About Visiongain
Visiongain Report Evaluation Form
List of Figures:
Figure 1: Functional Difference in Normal and Cystic Fibrosis Lung Cells
Figure 2: CFTR Chromosome Location
Figure 3: Sweat Testing
Figure 4: Median Predicted Survival Age for Patients Born with Cystic Fibrosis
Figure 5: Worldwide Disease Prevalence of Cystic Fibrosis, 2016 – 2026
Figure 6: US Disease Prevalence of Cystic Fibrosis, 2016 – 2026
Figure 7: Age Distribution of Patients with Cystic Fibrosis in the US, 2016
Figure 8: Age Distribution (%) of Patients with Cystic Fibrosis in the US, 2016
Figure 9: Epidemiology Trends of Patients with Cystic Fibrosis in Europe, 2016 – 2026
Figure 10: Age Distribution of Patients with Cystic Fibrosis in Europe, 2016
Figure 11: Age Distribution (%) of Patients with Cystic Fibrosis in Europe, 2016
Figure 12: Epidemiology Trends of Patients with Cystic Fibrosis in Canada, 2016 – 2026
Figure 13: Prevalence Rate of Cystic Fibrosis by Region, 2016
Figure 14: F 508 Del Mutation Spread US, 2016
Figure 15: F 508 Del Mutation Spread Europe, 2016
Figure 16: Worldwide Cystic Fibrosis Market, 2016-2026
Figure 17: Cystic Fibrosis Regional Market Split, 2016
Figure 18: Cystic Fibrosis Regional Market Split, 2021
Figure 19: Cystic Fibrosis Regional Market Split, 2026
Figure 20: US Cystic Fibrosis Market Forecasts, 2016-2026
Figure 21: Cost per Patient per Year in the US, 2016
Figure 22: YoY Price Growth of Top Cystic Fibrosis Products, 2016
Figure 23: Patients Treated by Various Cystic Fibrosis Drugs, 2016
Figure 24: Patients Share Captured in the US by Various Drugs, 2016
Figure 25: Market Share Captured in the US by Various Drugs, 2016
Figure 26: Europe Cystic Fibrosis Market Forecasts, 2016-2026
Figure 27: RoW Cystic Fibrosis Market Forecasts, 2016-2026
Figure 28: Comparative Cystic Fibrosis Market Forecasts by Region, 2016-2026
Figure 29: CFTR Modulators Market Forecasts, 2016-2026
Figure 30: Orkambi (Vertex Pharmaceuticals) Market Forecasts, 2016-2026
Figure 31: Kalydeco (Vertex Pharmaceuticals) Market Forecasts, 2016-2026
Figure 32: VX-661 + ivacaftor (Royalty Pharma) Market Forecasts, 2016-2026
Figure 33: Second corrector/VX-661/ivacaftor (Vertex Pharmaceuticals) Market Forecasts, 2016-2026
Figure 34: Comparative CFTR Modulators Market Share (%), 2021
Figure 35: Comparative CFTR Modulators Market Share (%), 2026
Figure 36: Comparative CFTR Modulators Market Forecast projections ($m), 2016 – 2026
Figure 37: Protein Transcription Modulators Market Forecasts ($m), 2016-2026
Figure 38: Pulmozyme (Roche) Market Forecasts ($m), 2016-2026
Figure 39: QR-010 Market Forecasts ($m), 2016-2026
Figure 40: Translarna Market Forecasts ($m), 2016-2026
Figure 41: Comparative Protein Transcription Modulators Market Share (%), 2016
Figure 42: Comparative Protein Transcription Modulators Market Share (%), 2021
Figure 43: Comparative Protein Transcription Modulators Market Share (%), 2026
Figure 44: Comparative Protein Transcription Modulators Market Forecast Projections, 2016 – 2026
Figure 45: Ceron (AbbVie) Market Forecasts ($m), 2016-2026
Figure 46: Cayston (Gilead Science) Market Forecasts ($m), 2016-2026
Figure 47: TOBI (Novartis) Market Forecasts ($m), 2016-2026
Figure 48: Comparative Pharmacological Class Market Share (%), 2016
Figure 49: Comparative Pharmacological Class Market Share (%), 2021
Figure 50: Comparative Pharmacological Class Market Share (%), 2026
Figure 51: Comparative Forecast Assessment by Pharmacological Class ($m), 2016 – 2026
Figure 52: Deal Count in CF 2000-2015
Figure 53: Vertex Project Overview by Development Stage
Figure 54: Vertex Project Overview by Therapeutic Area
Figure 55: Vertex Licensing and Acquisition Deals, 2009-2016
Figure 56: Vertex Key Product Sales (Historic and Forecasted), 2010-2020
Figure 57: Roche Project Overview by Development Stage
Figure 58: Roche Deal Count, 2010-2016
Figure 59: Roche Key Product Sales (Historic and Forecasted), 2010-2020
Figure 60: AbbVie Project Overview by Development Stage
Figure 61: AbbVie Deal Count, 2010-2016
Figure 62: AbbVie Key Product Sales (Historic and Forecasted), 2010-2020
Figure 63: Gilead Project Overview by Development Stage
Figure 64: Gilead Deal Count, 2010-2016
Figure 65: Gilead Key Product Sales (Historic and Forecasted), 2010-2020
Figure 66: Novartis Deal Count, 2010-2016
Figure 67: Novartis Key Product Sales (Historic and Forecasted), 2010-2020
List of Tables:
Table 1: Classes of CFTR Mutations
Table 2: Symptoms of Cystic Fibrosis
Table 3: Cystic Fibrosis Foundation Guidelines for Cystic Fibrosis Care
Table 4: Worldwide Cystic Fibrosis Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2026
Table 5: US Cystic Fibrosis Market Forecasts: Revenues ($m), AGR (%), CAGR (%), 2016-2026
Table 6: Patients Treated by Various Cystic Fibrosis Drugs in the US, 2016
Table 7: Europe Cystic Fibrosis Market Forecasts: Revenues ($m), AGR (%), CAGR (%), 2016-2026
Table 8: RoW Cystic Fibrosis Market Forecasts: Revenues ($m), AGR (%), CAGR (%), 2016-2026
Table 9: Comparative CF Market Forecasts by Region: Revenues ($m), AGR (%), CAGR (%), 2016-2026
Table 10: CFTR Modulators Market Forecasts: Revenues ($m), AGR (%), CAGR (%), 2016-2026
Table 11: Orkambi (Vertex Pharmaceuticals) Market Forecasts: Revenues ($m), AGR (%), CAGR (%), 2016-2026
Table 12: Kalydeco (Vertex Pharmaceuticals) Market Forecasts: Revenues ($m), AGR (%), CAGR (%), 2016-2026
Table 13: VX-661 + ivacaftor (Royalty Pharma) Market Forecasts: Revenues ($m), AGR (%), CAGR (%), 2016-2026
Table 14: Second corrector/VX-661/ivacaftor (Vertex Pharmaceuticals) Market Forecasts: Revenues ($m), AGR (%), CAGR (%), 2016-2026
Table 15: Comparative CFTR Modulators Market Forecasts: Revenues ($m), AGR (%), CAGR (%)
Table 16: Protein transcription modulators Market Forecasts: Revenues ($m), AGR (%), CAGR (%), 2016-2026
Table 17: Pulmozyme (Roche) Market Forecasts: Revenues ($m), AGR (%), CAGR (%), 2016-2026
Table 18: QR-010 Market Forecasts: Revenues ($m), AGR (%), CAGR (%), 2016-2026
Table 19: Translarna Market Forecasts: Revenues ($m), AGR (%), CAGR (%), 2016-2026
Table 20: Comparative Protein Transcription Modulators Market Forecasts by Region: Revenue ($m), AGR (%), CAGR (%), 2016-2026Region: Revenue ($m), AGR (%), CAGR (%), 2016-2026
Table 21: Ceron (AbbVie) Market Forecasts: Revenues ($m), AGR (%), CAGR (%), 2016-2026
Table 22: Cayston (Gilead Science) Market Forecasta: Revenues ($m), AGR (%), CAGR (%), 2016-2026
Table 23: TOBI (Novartis) Market Forecasts: Revenues ($m), AGR (%), CAGR (%), 2016-2026
Table 24: Comparative Protein Transcription Modulators Market Forecasts by Region: Revenues ($m), AGR (%), CAGR (%), 2016-2026
Table 25: US Product Launch – Key Therapies
Table 26: Europe Product Launch – Key Therapies
Table 27: Japan Product Launch – Key Therapies
Table 28: Patent analysis of Launched Products – Key Therapies
Table 29: Patent analysis of Phase 3 Products – Key Therapies
Table 30: Patent analysis of Phase 2 Products – Key Therapies
Table 31: Patent analysis of Phase 1 Products – Key Therapies
Table 32: Patent analysis of pre-clinical/research stage Products – Key Therapies
Table 33: Deal trend analysis in CF – 2000-2015
Table 34: Vertex Company Overview
Table 35: Vertex Key M&As
Table 36: Roche Company Overview
Table 37: Roche Key Deals
Table 38: AbbVie Company Overview
Table 39: AbbVie Key Deals
Table 40: Gilead Company Overview
Table 41: Gilead Key Deals
Table 42: Novartis Company Overview
Table 43: Novartis Key Deals
Table 44: Strengths and Weakness of the Cystic Fibrosis Market
Table 45: Opportunities and Threats for the Cystic Fibrosis Market
Table 46: Political, Economic, Social and technological Factors influencing Cystic Fibrosis Market

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report